AZ’s Tagrisso brings ‘unprecedented’ benefit in untreated NSCLC
Drug could become standard of care, says AZ
Drug could become standard of care, says AZ
R&D link-up with Harvard Fibrosis Network
Pharmaceutical Freeze Drying Technology
Formulation development for Safe Delivery to patient
SMi’s 2nd annual HPAPI Conference
Could antisense drug be a fatty liver disease blockbuster?
Wilson’s board has unanimously accepted the offer
vTv to stop all studies after STEADFAST trial failure